Publicacións en colaboración con investigadores/as de Centre François Baclesse (3)

2021

  1. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Journal of Thoracic Oncology

2020

  1. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study

    Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591

2016

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550